Please use this identifier to cite or link to this item:
Title: Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with Tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: Results from the ACTG A5175 PEARLS study
Authors: Connie Celum
Ting Hong
Anne Cent
Deborah Donnell
Rhoda Morrow
Jared M. Baeten
Cynthia Firnhaber
Beatriz Grinsztejn
Mina C. Hosseinipour
Umesh Lalloo
Mulinda Nyirenda
Cynthia Riviere
Jorge Sanchez
Breno Santos
Khuanchai Supparatpinyo
James Hakim
N. Kumarasamy
Thomas B. Campbell
Keywords: Medicine
Issue Date: 15-Mar-2017
Abstract: © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. Objective: Tenofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity against herpes simplex virus type 2 (HSV-2) and reduced HSV-2 acquisition as preexposure prophylaxis. Whether TDF-containing antiretroviral therapy (ART) reduces HSV-2 acquisition is unknown. Design: Secondary analysis of AIDS Clinical Trials Group A5175, a randomized, open-label study of 3 ART regimens among 1571 participants. Methods: HSV-2 serostatus was assessed at baseline, at study exit, and before a change in ART regimen. Results: Of 365 HSV-2-seronegative persons, 68 acquired HSV-2, with 24 receiving TDF-containing ART and 44 receiving ART without TDF (HSV-2 seroconversion incidence, 6.42 and 6.63 cases/100 person-years, respectively; hazard ratio, 0.89; 95% confidence interval,.55-1.44). Conclusions: HSV-2 acquisition was not reduced in HIVinfected, HSV-2-uninfected persons during TDF-containing ART.
ISSN: 15376613
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.